GTGiulia Tamborino

Giulia Tamborino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giulia Tamborino has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CAIX-targeted α therapy directed against hypoxic tumor cells in combination with immune checkpoint inhibitors in a syngeneic mouse tumor model

    by Sylvia T.M. Wenker, Mark W. Konijnenberg, Daphne Lobeek, Giulia Tamborino, Janneke D.M. Molkenboer-Kuenen, Gerben M. Franssen, Daan F. Boreel, Simone C Kleinendorst, Hans Peters, Johan Bussink, et al.

    Tumor hypoxia is a major factor in therapy resistance. A potential strategy to treat hypoxic tumors is targeted α therapy (TAT), since α particles can cause complex DNA damage independent of oxygen levels. Here, we investigate the potential of TAT as monotherapy and in combination with immune checkpoint inhibitors (ICI) to treat hypoxic tumors. Methods: Monoclonal anti-CAIX antibody DOTA-MSC3 was labeled with indium-111 (111In) or actinium-225 (225Ac), and binding to CAIX-expressing hypoxic tumor cells was determined in vitro. Subsequently, the in vivo biodistribution and dosimetry of radiolabeled DOTA-MSC3 was assessed in B16F10-OVA tumor-bearing mice, and its spatial distribution in the tumor (autoradiography) was correlated to CAIX expression measured by immunofluorescence. Finally, tumor growth and survival were determined upon treatment with [225Ac]Ac-DOTA-MSC3 with and without ICI. Results: 111In- and 225Ac-labeled DOTA-MSC3 bound specifically to CAIX-expressing hypoxic tumor cells. In vivo, uptake of both radiopharmaceuticals in B16F10-OVA tumors was spatially correlated with CAIX-positive hypoxic tumor regions. [225Ac]Ac-DOTA-MSC3 significantly prolonged survival of mice compared with PBS control (p=0.0032). Furthermore, the combination of [225Ac]Ac-DOTA-MSC3 and ICI significantly delayed tumor growth and prolonged survival compared with PBS control (p=0.0022 and p=0.0019, respectively). Conclusion: Overall, these results demonstrate first proof-of-concept of the potential of CAIX-TAT to treat hypoxic tumors by targeting CAIX-positive hypoxic tumor regions. CAIX-TAT combined with ICI was most effective in inhibiting tumor growth and prolonging survival of tumor-bearing mice. Future studies are required to investigate the radiobiological and immunological effects of CAIX-TAT, to guide optimization of this treatment in combination with ICI.

  • A framework for in-field and out-of-field patient specific secondary cancer risk estimates from treatment plans using the TOPAS Monte Carlo system

    by Isaac Meyer, Nils Peters, Giulia Tamborino, Hoyeon Lee, Alejandro Bertolet, Bruce Faddegon, Matthew M Mille, Choonsik Lee, Jan Schuemann, Harald Paganetti

    Objective. To allow the estimation of secondary cancer risks from radiation therapy treatment plans in a comprehensive and user-friendly Monte Carlo (MC) framework. Method. Patient planning computed tomography scans were extended superior-inferior using the International Commission on Radiological Protection’s Publication 145 computational mesh phantoms and skeletal matching. Dose distributions were calculated with the TOPAS MC system using novel mesh capabilities and the digital imaging and communications in medicine radiotherapy extension interface. Finally, in-field and out-of-field cancer risk was calculated using both sarcoma and carcinoma risk models with two alternative parameter sets. Result. The TOPAS MC framework was extended to facilitate epidemiological studies on radiation-induced cancer risk. The framework is efficient and allows automated analysis of large datasets. Out-of-field organ dose was small compared to in-field dose, but the risk estimates indicate a non-negligible contribution to the total radiation induced cancer risk. Significance. This work equips the TOPAS MC system with anatomical extension, mesh geometry, and cancer risk model capabilities that make state-of-the-art out-of-field dose calculation and risk estimation accessible to a large pool of users. Furthermore, these capabilities will facilitate further refinement of risk models and sensitivity analysis of patient specific treatment options.


  • Open Access

    Towards Effective CAIX-targeted Radionuclide and Checkpoint Inhibition Combination Therapy for Advanced Clear Cell Renal Cell Carcinoma

    by Simone C. Kleinendorst, Egbert Oosterwijk, Janneke Molkenboer-Kuenen, Cathelijne Frielink, Gerben M. Franssen, Daan F. Boreel, Giulia Tamborino, Manon Gloudemans, Merel Hendrikx, Dennis Kroon, et al.

    Background: Immune checkpoint inhibitors (ICI) are routinely used in advanced clear cell renal cell carcinoma (ccRCC). However, a substantial group of patients does not respond to ICI therapy. Radiation is a promising approach to increase ICI response rates since it can generate anti-tumor immunity. Targeted radionuclide therapy (TRT) is a systemic radiation treatment, ideally suited for precision irradiation of metastasized cancer. Therefore, the aim of this study is to explore the potential of combined TRT, targeting carbonic anhydrase IX (CAIX) which is overexpressed in ccRCC, using [ 177 Lu]Lu-DOTA-hG250, and ICI for the treatment of ccRCC. Methods: In this study, we evaluated the therapeutic and immunological action of [ 177 Lu]Lu-DOTA-hG250 combined with aPD-1/a-CTLA-4 ICI. First, the biodistribution of [ 177 Lu]Lu-DOTA-hG250 was investigated in BALB/cAnNRj mice bearing Renca-CAIX or CT26-CAIX tumors. Renca-CAIX and CT26-CAIX tumors are characterized by poor versus extensive T-cell infiltration and homogeneous versus heterogeneous PD-L1 expression, respectively. Tumor-absorbed radiation doses were estimated through dosimetry. Subsequently, [ 177 Lu]Lu-DOTA-hG250 TRT efficacy with and without ICI was evaluated by monitoring tumor growth and survival. Therapy-induced changes in the tumor microenvironment were studied by collection of tumor tissue before and 5 or 8 days after treatment and analyzed by immunohistochemistry, flow cytometry, and RNA profiling. Results: Biodistribution studies showed high tumor uptake of [ 177 Lu]Lu-DOTA-hG250 in both tumor models. Dose escalation therapy studies in Renca-CAIX tumor-bearing mice demonstrated dose-dependent anti-tumor efficacy of [ 177 Lu]Lu-DOTA-hG250 and remarkable therapeutic synergy including complete remissions when a presumed subtherapeutic TRT dose (4 MBq, which had no significant efficacy as monotherapy) was combined with aPD-1+aCTLA-4. Similar results were obtained in the CT26-CAIX model for 4 MBq [ 177 Lu]Lu-DOTA-hG250 + a-PD1. Ex vivo analyses of treated tumors revealed DNA damage, T-cell infiltration, and modulated immune signaling pathways in the TME after combination treatment. Conclusions: Subtherapeutic [ 177 Lu]Lu-DOTA-hG250 combined with ICI showed superior therapeutic outcome and significantly altered the TME. Our results underline the importance of investigating this combination treatment for patients with advanced ccRCC in a clinical setting. Further investigations should focus on how the combination therapy should be optimally applied in the future. Abstract Figure:

  • Open Access

    Effectiveness of staff radiation protection devices for interventional cardiology procedures

    by Christelle Huet, Jérémie Dabin, Joanna Domienik-Andrzejewska, Alexandre Hebre, Edilaine Honorio da Silva, Pasquale Lombardo, Giulia Tamborino, Filip Vanhavere


  • Open Access

    Modeling early radiation DNA damage occurring during [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy

    by Giulia Tamborino, Yann Perrot, Marijke De Saint-Hubert, Lara Struelens, Julie Nonnekens, Marion de Jong, Mark W. Konijnenberg, Carmen Villagrasa

    The aim of this study was to build a simulation framework to evaluate the number of DNA double-strand breaks (DSBs) induced by in vitro targeted radionuclide therapy (TRT). This work represents the first step toward exploring underlying biologic mechanisms and the influence of physical and chemical parameters to enable a better response prediction in patients. We used this tool to characterize early DSB induction by 177Lu-DOTATATE, a commonly used TRT for neuroendocrine tumors. Methods: A multiscale approach was implemented to simulate the number of DSBs produced over 4 h by the cumulated decays of 177Lu distributed according to the somatostatin receptor binding. The approach involves 2 sequential simulations performed with Geant4/Geant4-DNA. The radioactive source is sampled according to uptake experiments on the distribution of activities within the medium and the planar cellular cluster, assuming instant and permanent internalization. A phase space is scored around the nucleus of the central cell. Then, the phase space is used to generate particles entering the nucleus containing a multiscale description of the DNA in order to score the number of DSBs per particle source. The final DSB computations are compared with experimental data, measured by immunofluorescent detection of p53-binding protein 1 foci. Results: The probability of electrons reaching the nucleus was significantly influenced by the shape of the cell compartment, causing a large variance in the induction pattern of DSBs. A significant difference was found in the DSBs induced by activity distributions in cell and medium, as is explained by the specific energy (z¯) distributions. The average number of simulated DSBs was 14 DSBs per cell (range, 7–24 DSBs per cell), compared with 13 DSBs per cell (range, 2–30 DSBs per cell) experimentally determined. We found a linear correlation between the mean absorbed dose to the nucleus and the number of DSBs per cell: 0.014 DSBs per cell mGy−1 for internalization in the Golgi apparatus and 0.017 DSBs per cell mGy−1 for internalization in the cytoplasm. Conclusion: This simulation tool can lead to a more reliable absorbed-dose–to–DNA correlation and help in prediction of biologic response. Visual Abstract